Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Citi
Cantor Fitzgerald
Fish and Richardson
Mallinckrodt
Farmers Insurance
Chinese Patent Office
Deloitte
Harvard Business School

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GEODON

« Back to Dashboard

Clinical Trials for Geodon

Trial ID Title Status Sponsor Phase Summary
NCT00044655 Switching Medication to Treat Schizophrenia Completed National Institute of Mental Health (NIMH) Phase 4 This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00044655 Switching Medication to Treat Schizophrenia Completed Icahn School of Medicine at Mount Sinai Phase 4 This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00141271 A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression Completed Pfizer Phase 3 This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed. Subjects are required to undergo a washout period of at least 7 days of any prior med.
NCT00208208 Geodon (Ziprasidone) for Posttraumatic Stress Disorder Completed Pfizer Phase 4 Atypical antipsychotics have shown promise in the treatment of depression and anxiety, which are prominent symptoms of PTSD. The profile of the atypical antipsychotic, ziprasidone (Geodon), suggests possible anxiolytic and antidepressant properties. This research will assess the potential effectiveness of Geodon in civilian men and women who suffer from severe PTSD. Response to ziprasidone or placebo will be measured by Clinician Administered PTSD Scale (CAPS) and Treatment Outcomes PTSD Scale (TOP-8).
NCT00208208 Geodon (Ziprasidone) for Posttraumatic Stress Disorder Completed Creighton University Phase 4 Atypical antipsychotics have shown promise in the treatment of depression and anxiety, which are prominent symptoms of PTSD. The profile of the atypical antipsychotic, ziprasidone (Geodon), suggests possible anxiolytic and antidepressant properties. This research will assess the potential effectiveness of Geodon in civilian men and women who suffer from severe PTSD. Response to ziprasidone or placebo will be measured by Clinician Administered PTSD Scale (CAPS) and Treatment Outcomes PTSD Scale (TOP-8).
NCT00208559 Ziprasidone in Children With Autism: A Pilot Study Completed Drexel University College of Medicine Phase 2 The purpose of this study is to see if the drug, ziprasidone, is effective in treating problems in adolescent associated with autism.
NCT00215150 Geodon for the Treatment of Refractory Social Anxiety Disorder Completed Pfizer Phase 2 The purpose of this study is to examine the effectiveness and tolerability of augmentation treatment of ziprasidone to achieve remission among patients with social anxiety disorder (SAD) who did not remit on sertraline treatment alone
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Geodon

Condition Name

Condition Name for Geodon
Intervention Trials
Bipolar Disorder 15
Schizophrenia 14
Schizoaffective Disorder 6
Healthy 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Geodon
Intervention Trials
Disease 16
Bipolar Disorder 16
Schizophrenia 14
Depression 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Geodon

Trials by Country

Trials by Country for Geodon
Location Trials
United States 158
India 14
Malaysia 5
Russian Federation 4
Ukraine 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Geodon
Location Trials
New York 12
California 11
Massachusetts 11
Ohio 9
North Carolina 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Geodon

Clinical Trial Phase

Clinical Trial Phase for Geodon
Clinical Trial Phase Trials
Phase 4 15
Phase 3 6
Phase 2/Phase 3 2
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Geodon
Clinical Trial Phase Trials
Completed 31
Terminated 5
Recruiting 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Geodon

Sponsor Name

Sponsor Name for Geodon
Sponsor Trials
Pfizer 21
Massachusetts General Hospital 4
Duke University 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Geodon
Sponsor Trials
Other 52
Industry 25
NIH 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Dow
QuintilesIMS
Healthtrust
Chubb
Harvard Business School
Accenture
Teva
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.